• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Lopinavir-ritonavir not associated with clinical benefit in patients with severe COVID-19

byThomas Su,Alex Chanand1 others
April 8, 2020
in Infectious Disease, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial involving adults hospitalized with confirmed SARS-CoV-2 infection, treatment with lopinavir-ritonavir in addition to standard supportive care did not yield appreciable benefit.

2. No significant difference between groups was observed in mortality, viral RNA loads, or duration of detectability.

Evidence Rating Level: 2 (Good)

Study Rundown: The novel coronavirus SARS-Cov-2 is known to cause the respiratory illness Covid-19 in varying degrees of severity, but no therapeutic agents have been demonstrated to be effective in combating coronavirus infections. Lopinavir is an HIV type 1 aspartate protease inhibitor that has shown in vitro activity against both SARS and MERS, but the concomitant use of other drugs, the lack of randomization, and the dependence on historical control groups in previous trials has precluded analysis of its efficacy and safety. This open-label trial involving hospitalized adults with laboratory-confirmed COVID-19 found no significant difference in the time to clinical improvement between the lopinavir-ritonavir and standard-care groups. In addition, mortality and the percentage of patients with detectable viral RNA at various time points were similar between groups. While serious adverse events were less common in the lopinavir-ritonavir group, gastrointestinal adverse events occurred more frequently. Limitations of this study were that a significant percentage of patients in the treatment group were unable to complete the full course of administration and that the overall mortality was nearly twice as high as initially reported by descriptive studies. These findings limit the generalizability of the study’s results as it is possible that a less severely ill population may reap greater benefits from the trial regimen. Future studies involving more heterogeneous populations or different combinations of antiviral agents will continue to guide strategy in addressing this new pandemic.

Click here to read the study in NEJM

Relevant Reading: A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

In-Depth [randomized controlled trial]: 199 adults hospitalized with Covid-19 in Wuhan, China were individually randomized in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, orally) plus standard care or standard care alone, defined as supplemental oxygen, noninvasive and invasive ventilation, antibiotics, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation as needed. Placebos were not prepared due to the trial’s emergent nature. In the intention-to-treat population, no significant difference in time to clinical improvement was detected between groups (median, 16 days vs. 16 days; hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.85; P=0.09). In the modified intention-to-treat population, there was a small but significant difference in time to clinical improvement (median, 15 days vs. 16 days; hazard ratio, 1.39; 95% CI, 1.00 to 1.91). The time to clinical deterioration was also similar between groups (hazard ratio for clinical deterioration, 1.01; 95% CI, 0.76 to 1.34). These findings were independent of the timing of initiation of treatment (either within 12 days of the onset of symptoms or later). While duration of hospitalization did not vary between groups, lopinavir-ritonavir patients had a shorter stay in the ICU (median, 6 days vs. 11 days; difference, −5 days; 95% CI, −9 to 0). Finally, while low-grade gastrointestinal adverse events were more common in the treatment group, serious adverse events occurred less frequently (20% vs 32%).

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspartate protease inhibitorCoronavirusLopinavir-ritonavirSARS-CoV-2
Previous Post

Inhibition of inflammation through interleukin pathway may be protective against anemia

Next Post

#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19
StudyGraphics

#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19

August 12, 2024
Next Post
#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

AAP recommends disaster preparedness measures for children

Early childhood behaviors and family structure associated with peer victimization

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.